|Author:||Andrea S Lear|
|Clinic:||University of Tennessee|
|City, State, ZIP:||Knoxville, TN 37996|
M. Wright, BS
A. Needleman, DVM
J. Schaffer, DVM, PhD
R. Videla , DVM, DACVIM, MS
A. Lear, DVM, PhD, DACVIM, MS
1Dpeartment of Large Animal Clinical Sciences, University of Tennessee College of Veterinary Medicine, Knoxville TN 37996, USA
2Dpeartment of Biomedical Sciences, University of Tennessee College of Veterinary Medicine, Knoxville TN 37996, USA
A double blinded, clinical trial was performed to meet this objective. Fifty-seven adult alpacas were enrolled in the trial and administered 2 g of COWP or placebo control capsule twice during the 90 day trial period. At 15-day intervals, fecal samples were collected and Modified McMaster’s exams were performed as well as physical examinations, including FAMACHA and body condition score (BCS). Hematocrit concentrations were measured every 30 days. Analysis of variance was conducted with SAS (GLM procedure, SAS Institute, Cary, NC) and least square means (LSD) compared with Tukey adjustment (HSD) at 5% significance level was used to compare treatment groups. Mean fecal egg counts were analyzed by repeated measures.
The results showed an effective decrease in fecal egg counts in animals administered COWP compared to controls (P = 0.03) along with an increase in BCS (P = 0.05) over the trial period. No significant difference in FAMACHA or hematocrit concentration (P > 0.05) was observed between treatment groups over time. Clinical evidence of copper toxicity was not observed during the trial.
Oral administration of COWP appears to be a safe and effective method of reducing FEC in adult camelids.